 The study found that trustusumabdruxtecin, TDXD, showed promising activity in patients with her two, positive metastatic colorectal cancer, MCRC, who had progressed on two or more previous treatments. The study also demonstrated that TDXD was well tolerated and had a manageable safety profile. This article was authored by Tokayuki Yoshino, Maria Di Bartolomeo, Kamal Rogov, and others.